ADMA Biologics, Inc. (ADMA)
NasdaqGM
Price as at 1 Oct 2026, 20:55 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
ADMA Biologics, Inc. trades at $9.93. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About ADMA Biologics, Inc.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
14 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Capital Research Global, Capital Research Global Investors$73.29M · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$44.15M · 0.0% of book
- Stanley Druckenmiller, Duquesne Family Office LLC$23.30M · 0.5% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$16.91M · 0.0% of book
- Terry Smith, Fundsmith LLP$13.81M · 0.1% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in ADMA
Trades in ADMA disclosed by members of Congress and executive-branch officials, latest first:
- Donald J Trump · Executive branchSell · $15,001 - $50,000 · traded 15 May 2026 · disclosed 1 Jul 2026
- Donald J Trump · Executive branchBuy · $50,001 - $100,000 · traded 30 Apr 2026 · disclosed 1 Jul 2026
- Donald J Trump · Executive branchSell · $1,001 - $15,000 · traded 29 Jul 2024 · disclosed 22 Sept 2026
- Donald J Trump · Executive branchBuy · $15,001 - $50,000 · traded 22 Jun 2024 · disclosed 22 Aug 2026
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Which funds own ADMA?
14 of the institutions we track reported a position in ADMA in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its ADMA data?
Fundamentals for ADMA come from company filings and exchange data, as listed on NasdaqGM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 20:55 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ADMA, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.